Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal
Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up…
Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up…
The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after…
Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO…
Affimed from Heidelberg had a 'formative year' (hmm) in 2015. Major highlights include raising of €52.6M,…
Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more…
Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of…
The World Leader in the Immuno-Oncology field has teamed up with a major German Investor…
Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted…
Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E…